SCHEMBL6840352

SCHEMBL6840352

Cc1ccc(-c2nc(C)cs2)cn1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.64
CYP2E1 P05181 1/20 0.64
CYP2A6 P11509 1/20 0.64
CYP2C9 P11712 1/20 0.64
CYP2B6 P20813 1/20 0.64
PDE10A Q9Y233 2/20 0.47
AOC3 Q16853 2/20 0.43
CYP19A1 P11511 5/20 0.42
HPGDS O60760 2/20 0.41
PIK3CD O00329 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PI4KA P42356 1/20 0.41
PIK3CG P48736 1/20 0.41
PI4KB Q9UBF8 1/20 0.41
AXL P30530 1/20 0.40
PBRM1 Q86U86 1/20 0.40
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
TLR9 Q9NR96 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4308509 0.84 CYP2E1 (0.46) CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL13680530 0.84 CYP2A6 (0.54) CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL8198560 0.83 CYP3A4 (0.60) CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL7905176 0.81 CYP3A4 (0.58) CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL19758243 0.81 RAB9A (0.64) CYP19A1HPGDSAXLPBRM1MKNK1
SCHEMBL13852580 0.81 CYP2A6 (0.44) CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL13680575 0.81 CYP2E1 (0.51) CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL13680539 0.81 CYP19A1 (0.61) CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL13680744 0.80 CYP3A4 (0.53) CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL13680533 0.80 CYP2E1 (0.50) CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653141-B2 HIV protease inhibiting compounds ABBVIE INC. (US) 2014-02-18 US disclosed
US-20130023463-A1 HIV PROTEASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 2013-01-24 US disclosed
EP-2216334-B1 HIV protease inhibiting sulfonamides ABBOTT LAB (US) 2012-10-31 EP disclosed
US-8193227-B2 HIV protease inhibiting compounds ABBOTT LABORATORIES (US) 2012-06-05 US disclosed
US-20110003827-A1 HIV protease inhibiting compounds ABBVIE INC. 2011-01-06 US disclosed
US-7696226-B2 HIV protease inhibiting compounds ABBOTT LABORATORIES (US) 2010-04-13 US disclosed
US-7582658-B2 Bicyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-09-01 US disclosed
US-7582658-B2 Bicyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-09-01 US disclosed
US-20050159469-A1 HIV protease inhibiting compounds ABBVIE INC. 2005-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003827-A1 HIV protease inhibiting compounds SERPINB1, HPN, DNPEP CYP3A4 764/4885CYP2E1 2016/4885CYP2A6 1882/4885
US-20130023463-A1 HIV PROTEASE INHIBITING COMPOUNDS SERPINB1, HPN, DNPEP CYP3A4 764/4885CYP2E1 2016/4885CYP2A6 1882/4885
US-20050159469-A1 HIV protease inhibiting compounds SERPINB1, HPN, DNPEP CYP3A4 764/4885CYP2E1 2016/4885CYP2A6 1882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.